Aptevo Therapeutics APVO 深 沪
等待开盘 08-21 09:30:00 美东时间
2.76
+0.030
+1.10%
华盛通- 最 高2.9115
- 今 开2.74
- 成交量 6.38万股
- 最 低 2.7233
- 昨 收 2.73
- 总市值 497.34万
- 52周最高 48.78
- 市盈率 静 --
- 换手率 3.54%
- 52周最低 2.60
- 委 比 90.48%
- 总股本 180.20万
- 历史最高 68020444.80
- 量 比 1.03
- 振 幅 6.89%
- 历史最低 2.60
- 每 手 1
- 风险率 10.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share from the same period last year.
08-14 20:32
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing
Aptevo Therapeutics ( ($APVO) ) has issued an update. On August 12, 2026, Aptev...
08-14 05:20
Aptevo Therapeutics shares are trading lower. The company announced exercise of existing warrants and PIPE for $4.5 million gross proceeds.
Aptevo Therapeutics shares are trading lower. The company announced exercise of existing warrants and PIPE for $4.5 million gross proceeds.
08-13 00:35
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Shares of Ultra Clean Holdings Inc (NASDAQ:UCTT) rose sharply in pre-market trading after the company announced the appointment of Michael Keogh as CFO. The company appoints Michael Keogh as CFO, effective Aug. 25, succeeding Sheri Savage. Ultra Clean shares jumped 6.5% to $107.50 in pre-market trad...
07-09 16:53
美股夜盘 | Republic Power涨38.76%，巨龙在线涨22.55%
Tvardi Therapeutics Inc.涨-10.80%；Dreamland涨-9.80%；有信科技涨-9.33%
07-09 08:05
Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology Programs
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform
05-27 20:09
Aptevo Therapeutic Announces 87% Clinical Benefit Rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection
The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with venetoclax and azacitidine.
05-06 20:10
Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of $(237.60) per share
03-26 20:55
Aptevo Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine In Newly Diagnosed AML Patients; Trials Deliver 86% Clinical Benefit Rate With Zero Patients Experiencing Common Symptom Of CRS
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc.
03-10 20:16
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Icecure Medical (NASDAQ:ICCM) shares moved upwards by 17.7% to $0.68 d...
03-02 20:05
